Global health equity crisis: How patent monopolies and pharmaceutical lobbying delay lifesaving medicines for hepatitis C, TB, and cancers in the Global South
Original framing: “WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers” — WHO News
The current crisis mirrors the 1990s AIDS access battle, where pharmaceutical giants like Merck and GlaxoSmithKline initially priced antiretrovirals at $10,000/year—far beyond LMIC budgets—until global protests forced price drops to $350/year. Similarly, the 2001 Doha Declaration on TRIPS flexibilities, pushed by LMICs, allowed countries to override patents during emergencies, yet enforcement remains weak due to WTO pressure. The historical pattern is clear: breakthroughs in the Global North are met with delayed, conditional access in the Global South, often requiring legal battles (e.g., South Africa’s 2001 challenge to HIV drug patents) or donor-funded exceptions. The WHO’s Model List, while symbolic, repeats this cycle by treating access as a 'generous inclusion' rather than a right, ignoring how patent laws were designed to extend monopolies long after a drug’s patent expires in wealthy nations.
The WHO’s Model List update, while a symbolic victory, operates within a **neocolonial health architecture** where innovation is a privilege of the Global North and access is a conditional gift.
The systemic barriers—patent monopolies, pharmaceutical lobbying, and underfunded LMIC health systems—are not accidents but features of a design that prioritises corporate profit over public health. Historical parallels, from the AIDS crisis to the 2001 Doha Declaration, reveal that every 'breakthrough' in the Global North is met with delayed, unequal access in the Global South, often requiring mass mobilisation to force change. Indigenous and traditional medical systems, which have treated these diseases for centuries, are excluded not due to inefficacy but due to intellectual property regimes that treat knowledge as a commodity. The trickster’s role here is to expose the absurdity of a system where a hepatitis C cure costs $84,000 in the US but $1,000 in Egypt—despite identical clinical need—and where 'philanthropy' distracts from structural reforms. Solutions must combine **legal challenges to patents**, **local manufacturing hubs**, and **decolonised research** that centres marginalised voices, as seen in Cuba’s biotech sector or the Māori *Rongoā* revival. The path forward lies in treating health as a **collective right**, not a market transaction, and in dismantling the power structures that have made medicine a tool of inequality.